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INTRODUCTION
Genome-scale sequencing inevitably leads to the identifica-
tion of many genomic variants with vastly differing clinical rel-
evance, which requires development of innovative categorical 
approaches for informed consent, analysis, and return of results. 
Clinical genomic sequencing for suspected monogenic disorders 
may identify millions of genetic variants in a single patient, with 
only one or two “diagnostic” variants likely to explain the molec-
ular etiology (“primary” results). Virtually all of the remaining 
variants are “incidental” to the original indication for analysis, 
although the term “secondary findings” is now the preferred 
term for such results when sought in a systematic fashion.1
We previously proposed a framework for organizing potential 
incidental/secondary findings into “bins” categorized by clini-
cal validity and clinical utility2 and developed provisional lists 
of binned genes.3 Our goal is to categorize potential findings 
before their discovery in a patient to guide informed decision 
making and return of results. As part of a National Human 
Genome Research Institute–funded Clinical Sequencing 
Exploratory Research project called “North Carolina Clinical 
Evaluation by Next-gen Exome Sequencing (NCGENES),” we 
assembled a Locus-Variant Binning Committee (LVBC) to 
refine a category of genomic findings that we call “bin 1”—the 
list of clinically actionable genes to be analyzed for pathogenic 
variants and returned as part of the routine results.4 Similar 
efforts are underway at other institutions and organizations.5–7
Recognizing that an expert consensus-based approach with-
out a clear definition and framework for adjudicating action-
ability could lead to inconsistent and arbitrary results, the 
LVBC developed a semiquantitative metric for determining the 
clinical actionability of gene–disease pairs. This metric explic-
itly recognizes that actionability is a continuum, not a binary 
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Purpose: As genome-scale sequencing is increasingly applied in clin-
ical scenarios, a wide variety of genomic findings will be discovered 
as secondary or incidental findings, and there is debate about how 
they should be handled. The clinical actionability of such findings 
varies, necessitating standardized frameworks for a priori decision 
making about their analysis.
Methods: We established a semiquantitative metric to assess five 
elements of actionability: severity and likelihood of the disease out-
come, efficacy and burden of intervention, and knowledge base, with 
a total score from 0 to 15.
Results: The semiquantitative metric was applied to a list of putative 
actionable conditions, the list of genes recommended by the Ameri-
can College of Medical Genetics and Genomics (ACMG) for return 
when deleterious variants are discovered as secondary/ incidental 
findings, and a random sample of 1,000 genes. Scores from the list 
of putative actionable conditions (median = 12) and the ACMG list 
(median  =  11) were both statistically different than the randomly 
selected genes (median = 7) (P < 0.0001, two-tailed Mann-Whitney 
test).
Conclusion: Gene–disease pairs having a score of 11 or higher rep-
resent the top quintile of actionability. The semiquantitative metric 
effectively assesses clinical actionability, promotes transparency, and 
may facilitate assessments of clinical actionability by various groups 
and in diverse contexts.
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state.8,9 That being said, we think that it is vital to define a core 
set of gene–disease pairs that reach a sufficient threshold of 
clinical actionability to be considered as part of the routine 
results of a genome-scale diagnostic test.
In parallel to the efforts of NCGENES, the Evidence-based 
Genomic Applications in Practice and Prevention Working 
Group established an evidence-based review procedure consist-
ing of a rapid, sensitive screen for genes with possible actionabil-
ity; structured data gathering organized around the elements 
of actionability articulated by the LVBC and detailed herein; 
and provided assessment by an expert deliberative committee.10 
Such a framework will be most useful, not for definitively deter-
mining actionability, but rather for identifying the minority of 
genes in the human genome that should undergo further scru-
tiny as possibly actionable in a given specific context.
The 2013 recommendations for analysis and return of 
certain highly actionable incidental/secondary findings by 
the American College of Medical Genetics and Genomics 
(ACMG) used a deliberative consensus method to identify 
gene–disease pairs within which clearly pathogenic variants 
should be returned as part of clinical genome-scale sequenc-
ing.5 These recommendations were met with criticisms,11–13 
among which were concerns about the process by which 
the recommended gene list was developed. Also noted were 
concerns that some genes on the recommended list may not 
reach an evidentiary threshold sufficient to justify being 
returned as incidental/secondary findings. The development 
of a clear framework for the assignment of clinical actionabil-
ity is therefore a necessary step toward formalizing such judg-
ments and making assessments reproducible and updatable.
MATeRIALs AND MeTHODs
semiquantitative metric categories and scoring rules
The LVBC established five core characteristics of clinical 
actionability, with particular emphasis on the ramifications of 
finding a clearly pathogenic variant in a person without signs or 
symptoms of the disease (Table 1). The five characteristics are 
reflected by the following questions:
Table 1 Semiquantitative metric framework, questions, scores, and examples
Category Level score Notes/examples
Severity of disease: “What is the nature of the 
threat to health for an individual carrying a 
deleterious allele in this gene?”
Sudden death or 
inevitable death
3 Cardiac arrhythmia, vascular dissection, fatal infantile 
neurodegenerative conditions
Possible death due to 
illness or comorbidity
2 Cancer, organ failure, moderate to severe intellectual 
disability
Modest morbidity 1 Mild to moderate intellectual disability, physical limitations, 
early-onset neurosensory deficits
Minimal health impact 0 Benign enzyme defects, nonmedical traits, later-onset 
neurosensory deficits
Likelihood of disease: “What is the chance that a 
serious threat will materialize?” (somewhat akin to 
penetrance)
>50% 3 Most individuals develop the severe outcome
6–49% 2 Some individuals develop the severe outcome
1–5% 1 Few individuals develop the severe outcome
<1% 0 Outcome is very rare or cannot be reasonably estimated
Efficacy of intervention: “How effective are 
the interventions for preventing harm in a 
presymptomatic individual?”
Highly effective 3 Nearly all individuals have substantial benefit
Moderately effective 2 The majority of individuals have some benefit
Minimally effective 1 The majority of individuals have marginal benefit, or the 
minority of individuals have substantial benefit
Ineffective/no 
interventions available
0 No individuals benefit; only watchful waiting recommended, 
or symptomatic treatments when disease manifests
Burden of intervention: “What are the burdens 
or potential harms of initiating interventions in a 
presymptomatic individual?”
Very low burden 3 Yearly screenings, routine medications, minor dietary/
lifestyle modification
Somewhat 
burdensome
2 Invasive screening, significant lifestyle alteration, 
medications with a substantial chance of side effects or 
more intensive delivery regimens, transplantation with rare 
complications
Moderately 
burdensome
1 Removal of a nonvital organ, transplantation with frequent 
complications
Highly burdensome 0 Removal of a vital organ
Knowledge base: “What is the evidence base for 
decisions about the natural history of the disease 
and interventions used for preventing serious 
outcomes?”
Substantial evidence 3 All categories scored confidently, high-quality review or 
practice guideline
Moderate evidence 2 Strong primary literature, some details scored by analogy to 
another well-known disorder
Minimal evidence 1 Unable to confidently score one or more categories, sparse 
primary literature or few reported patients
Controversial or poor 
evidence
0 Uncertain natural history of disease, primary literature 
lacking or controversial
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1. Severity: “What is the nature of the potential adverse 
health outcome in an individual carrying a deleteri-
ous allele in this gene?” Severity is scored from minimal 
health impact to modest morbidity to sudden/inevitable 
death.
2. Likelihood: “What is the chance that this adverse out-
come will manifest?” Scoring for this category uses 
brackets of likelihood and is similar to penetrance.
3. Efficacy of intervention: “How effective are the estab-
lished interventions for preventing the harmful out-
come?” Efficacy of the intervention is scored from lack of 
demonstrable efficacy to highly effective intervention.
4. Burden of intervention: “How acceptable are the inter-
ventions in terms of the burdens or risks placed on the 
individual?” The burden or acceptability of the interven-
tion is scored from highly consequential to minimally 
burdensome intervention.
5. Knowledge base: “How much is known about the gene, 
condition, and intervention to allow scoring in each cat-
egory?” Knowledge is scored from controversial or poor 
evidence to substantial evidence.
All five criteria are scored on a scale of 0–3. The “outcome” 
and “intervention” are defined in advance and the other 
components of the metric are scored with respect to these 
parameters. It is critical to consider outcomes together with 
corresponding interventions to balance the clinical effects 
expected by natural history against the benefits and harms of 
these interventions in individuals who have not manifested 
symptoms of disease.
Gene sets scored
To judge the ability of the metric to distinguish between condi-
tions that vary widely in terms of clinical actionability, three lists 
of genes were scored: (i) a list of 161 provisionally actionable 
genes3 (hereafter referred to as “bin 1 genes”); (ii) a list of 57 genes 
originally recommended by the ACMG4 (hereafter referred to as 
“ACMG genes”); and (iii) a list of 1,000 genes randomly selected 
from the National Center for Biotechnology Information RefSeq 
database (hereafter referred to as “random genes”). The ran-
dom genes were selected from a 7 October 2013 RefSeq down-
load using an in-house python script utilizing the “random” 
module. They were cross-referenced against Online Mendelian 
Inheritance in Man (http://www.omim.org) and OrphaNet 
 (http://www.orphadata.org/cgi-bin/inc/ordo_orphanet.inc.php) 
and manually curated to identify those with disease associations 
as of that time. The majority of the random genes (889/1,000) 
had no documented disease association, were associated only 
with somatic mutations, or had a modest influence on disease 
risk based on association study data. These conditions scored 0 
by default and were excluded from further analysis.
Although the ACMG’s recommended list has subsequently 
been reduced to 56, all 57 original genes were analyzed with the 
expectation that the removed gene (NTRK1) would prove to be 
an outlier with regard to clinical actionability.
In addition, a list of “other” gene–disease pairs were scored, 
including conditions with phenotypes overlapping those of 
genes considered to be potentially actionable, disorders that 
are allelic to others that were scored, or conditions that were 
selected to evaluate the range of scores obtained for conditions 
considered not to be actionable. Scores for these “other genes” 
are included in the overall analysis but were not subject to statis-
tical comparisons between lists because of their heterogeneity.
Assessment and consensus scoring
The multidisciplinary LVBC included clinical geneticists, 
genetic counselors, physicians from other specialties such as 
cardiology and neurology, a primary care physician, clinical 
laboratorians, and ethicists. Information about  gene-disease 
relationships was obtained from OMIM, GeneReviews,14 
Figure 1  semiquantitative metric scores. (a) Summary of overlap 
between the gene lists analyzed. The American College of Medical Genetics 
and Genomics (ACMG) genes included 26 gene–disease pairs (25 not 
including NTRK) that were not among the bin 1 genes. Conversely, 130 bin 
1 genes were not among the ACMG genes. Of the 111 random genes with 
a defined disease association, 4 overlapped with the bin 1 genes (ANK2, 
BRIP1, COL1A2, PROC), 1 overlapped with the ACMG genes (NTRK1), and 
1 gene overlapped both lists (PTEN). The Locus-Variant Binning Committee 
also evaluated 80 other gene–disease pairs, including alternative phenotypes 
for some genes, or different genes with similar disease phenotypes. One 
of these genes was on the ACMG list (NF2) and two were on the random 
list (CASQ2 and MAX). (b) Distribution of semiquantitative metric scores. 
Box-whisker plots showing the median, 25th–75th percentiles (box), and 
5th–95th percentiles (whiskers) of the scores for the bin 1 gene list, ACMG 
gene list, random gene list, and other gene list. Asterisks indicate statistically 
significant differences (P < 0.0001, two-tailed Mann-Whitney test).
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Table 2 Examples of semiquantitative metric scores for selected genes
Gene
OMIM 
phenotype List severity Likelihood efficacy Burden
Knowledge 
base Total
ACADM 201450 Bin 1 3 3 3 3 3 15
Notes: Medium-chain acyl-CoA dehydrogenase deficiency is associated with a high lifetime risk of hypoglycemic episodes provoked by fasting or illness. 
These episodes can be fatal but are highly preventable through avoidance of fasting or provision of intravenous fluids with dextrose during illnesses.18
MLH1 609310 Bin 1, ACMG 2 3 3 2 3 13
Notes: Lynch syndrome is a highly penetrant cancer predisposition syndrome in which individuals are at risk for colorectal cancer as well as other cancers. 
Increased colonoscopic screening is highly effective at preventing deaths due to colon cancer.19
FBN1 154700 Bin 1, ACMG 3 2 2 3 3 13
Notes: Marfan syndrome is characterized by skeletal, eye, and cardiovascular involvement; the most severe aspect is increased risk for aortic aneurysm 
and dissection. Screening of the aortic root and arch for evidence of dilation can effectively identify individuals at high risk for dissection and allow 
initiation of preemptive definitive surgical management.20
LDLR (Heterozygous) 143890 Bin 1, ACMG 2 3 2 3 3 13
Notes: Familial hypercholesterolemia results in elevated risk for death due to coronary artery disease. Treatment with lipid-lowering medications can 
somewhat mitigate the risk in affected individuals.21
F8 306700 Bin 1 2 3 3 2 3 13
Notes: Hemophilia presents a risk for severe bleeding that can result in severe chronic morbidity or fatality. Recombinant clotting factor is an effective 
preventive measure.22
HFE (C282Y homozygous) 235200 Bin 1 2 1 3 3 3 12
Notes: Hemochromatosis leads to iron overload that can cause cirrhosis, cardiomyopathy, and endocrine dysfunction. Although biochemical evidence of 
abnormal iron homeostasis is seen in the majority of patients, less than 10% develop severe end-organ manifestations. Biochemical screening followed 
by therapeutic phlebotomy is highly effective for reducing morbidity.23
PTEN 153480 Bin 1, ACMG, random 2 3 2 3 2 12
Notes: PTEN hamartoma syndrome is associated with an increased risk for several malignancies, including breast cancer. Penetrance is high, and it is 
expected that increased screening will benefit at-risk individuals, by analogy to other cancer predisposition syndromes. However, specific data regarding 
screening protocols are lacking.24
CASQ2 611938 Random, other 3 3 2 3 1 12
Notes: Catecholaminergic polymorphic ventricular tachycardia is characterized by episodes of arrhythmia induced by adrenergic stress. Patients can 
present with syncope or sudden cardiac death. Limited data suggest that intervention with β-blockers and flecainide can be effective, and in some cases 
implantable cardioverter-defibrillator placement is required.25,26
MYH7 115196 ACMG 3 1 3 3 2 12
Notes: Hypertrophic cardiomyopathy can lead to sudden cardiac death in a small proportion of affected individuals. Management includes cardiology 
surveillance and risk stratification, with more aggressive interventions in those who develop symptoms.27,28
SLC2A1 606777 Random 2 3 2 2 2 11
Notes: Glucose transporter type 1 deficiency syndrome has a broad phenotypic spectrum including individuals with seizures and/or complex movement 
disorder. Symptoms show substantial improvement with a ketogenic diet.29,30
F5 Leiden (homozygous) 188055 Other 2 3 2 2 2 11
Notes: This specific mutation in the F5 gene causes resistance to cleavage and inactivation by protein C. In the homozygous state, the result is a 
substantially elevated risk for venous thrombosis, which in some cases can lead to mortality due to pulmonary embolism. Awareness of this tendency 
allows measures to be taken to prevent immobility, reducing the chance of a clot developing.31,32
SDHB 115310 Bin 1, ACMG 2 2 1 3 2 10
Notes: Heterozygous pathogenic variants in SDHB cause a syndrome of predisposition to paragangliomas, which can become malignant. Biochemical 
screening and imaging are recommended in asymptomatic individuals, with the expectation that this protocol would be somewhat effective for detecting 
tumors at smaller size and earlier stage.33,34
ALB 615999 Random 1 1 3 3 2 10
Notes: Individuals with familial dysalbuminemic hyperthyroxinemia are clinically euthyroid, although a variant in the albumin gene leads to preferential 
affinity for thyroxine (T4). Some patients have been mistakenly treated for hyperthyroidism, leading to modest morbidity, which could be avoided simply 
by foreknowledge about this relatively benign phenotype.35
ACMG, American College of Medical Genetics and Genomics; PTEN, phosphatase and tensin homolog.
aNTRK1 was included in an original version of the ACMG publication but removed from the final published list.
Table 2 Continued on next page
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PubMed searches, and clinical guidelines, when available. 
Members of the LVBC prepared the evidence review, typically 
with a single member assigned primary responsibility for each 
gene–disease phenotype pair. The committee met regularly to 
review the evidence and to agree on a score for each element of 
the semiquantitative metric or direct additional review.
To mitigate the subjective nature of assessing certain cat-
egories and to enhance consistency between scores, the LVBC 
arrived at a series of scoring conventions (examples in Table 1). 
Scores for categories 1 (severity) and 2 (likelihood) are linked 
to the same specific outcome, either the most severe potential 
outcome or what is generally considered the primary outcome 
for the disease. However, scores for a given gene–disease pair 
can be calculated for more than one outcome of interest to 
account for disease pleiotropy. For example, different scores can 
be calculated for BRCA1 depending on whether the outcome 
of interest is breast cancer or ovarian cancer. In effect, catego-
ries 1 and 2 reflect the medical implications of disease faced 
by an individual with a pathogenic finding. Scores for catego-
ries 3 (efficacy) and 4 (burden) reflect specific presymptomatic 
interventions targeted to the outcome described in categories 
1 and 2 (e.g., bilateral risk-reducing mastectomy or bilateral 
 salpingo-oophorectomy per the example of BRCA1). The semi-
quantitative metric thus approximates the concept of clinical 
utility by balancing the potential benefits and harms of inter-
vention when an incidental/secondary finding is discovered in 
a presymptomatic individual.
ResULTs
A total of 1,213 unique genes were evaluated using the semi-
quantitative metric (Supplementary Table S1 online). After 
removing genes not implicated in a single-gene disorder, 324 
unique genes representing 372 gene–disease pairs were scored. 
These genes included 161 bin 1 genes, 57 ACMG genes, and 
111 random genes associated with defined monogenic disor-
ders. There was some degree of overlap between these lists, 
as depicted in Figure  1a. In cases where the random genes 
were associated with more than one condition, the highest of 
the scores was chosen to represent the random gene–disease 
pair; scores for additional gene–disease pairs were tallied in the 
“other” category.
The median score of the bin 1 genes was 12 (range 0–15); 
84/161 gene–disease pairs scored ≥12, while 29/161 pairs 
scored <10. The median score for the ACMG genes was 11 
(range 7–14); 25/57 gene–disease pairs scored ≥12, while 
11/57 pairs scored <10. The NTRK1 gene, originally included 
on ACMG’s preliminary recommended list and subsequently 
dropped, scored 7. In comparison, the median score of the 111 
random genes was 7 (range 1–13); only 14/111 gene–disease 
pairs scored ≥12, while 81/111 pairs scored <10. Figure  1b 
shows the distribution of scores for all of the pairs. The distribu-
tions of scores for the bin 1 genes and the ACMG genes are not 
significantly different from each other, but both lists are signifi-
cantly different than the random genes (P < 0.0001,  two-tailed 
Mann-Whitney test), indicating that the semiquantitative 
FLCN 135150 Bin 1 2 1 2 3 1 9
Notes: Birt-Hogg-Dubé syndrome is a hereditary cancer predisposition syndrome associated with benign hamartomatous skin lesions, benign and 
malignant kidney neoplasms, and lung cysts leading to spontaneous pneumothorax. Screening protocols are recommended and assumed to be 
somewhat effective at detecting kidney tumors, but the evidence base for screening is limited.36
TNNI3 613690 ACMG 3 1 1 3 1 9
Notes: As with MYH7, the TNNI3 gene is associated with cardiomyopathy and risk for sudden death.27 However, the degree to which screening can be an 
effective strategy for preventing this outcome in individuals with TNNI3 pathogenic variants is less well known.
MYLK 603776 ACMG 3 0 1 3 1 8
Notes: As with FBN1, pathogenic variants in MYLK are reported to be associated with increased risk of aortic dissection. However, the penetrance is 
essentially unknown and the pathophysiology seems to involve dissections and not aneurysms, limiting the efficacy of screening.37 The overall knowledge 
base about MYLK-associated disease is somewhat limited.
GCK 125851 Bin 1 1 1 1 3 2 8
Notes: Maturity-onset diabetes of the young results in a rare form of insulin-dependent diabetes. However, these individuals rarely exhibit diabetic 
ketoacidosis, and overall complications of diabetes are low in this disorder.38
NAGLU 252920 Random 3 3 0 0 2 8
Notes: Pathogenic variants in NAGLU cause mucopolysaccharidosis type IIIB (Sanfilippo B), a lysosomal storage disease that leads to significant morbidity 
and mortality but has no effective preventive measures at this time. Supportive treatments for symptomatic manifestations are the mainstay of care but 
would not be expected to substantially alter outcomes.39
NTRK1 155240 ACMGa 2 0 3 2 0 7
Notes: The NTRK1 gene has been implicated in predisposition to medullary thyroid carcinoma, which in principle could be effectively prevented through 
prophylactic thyroidectomy. However, the evidence supporting causality of germ-line variants in cancer predisposition is weak, and there is insufficient 
data with which to estimate penetrance.40
ACMG, American College of Medical Genetics and Genomics; PTEN, phosphatase and tensin homolog.
aNTRK1 was included in an original version of the ACMG publication but removed from the final published list.
Table 2 Continued
Gene
OMIM 
phenotype List severity Likelihood efficacy Burden
Knowledge 
base Total
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metric effectively distinguishes between gene–disease pairs 
that were qualitatively deemed to be actionable in earlier efforts 
from those that would not be enriched for actionability. Table 2 
presents several scoring examples, and all scores are included in 
Supplementary Table S1 online.
Among the gene–disease pairs scoring highest using this 
metric were MLH1 (associated with Lynch syndrome) at 13 
and RYR1 (malignant hyperthermia) at 12. Despite its low pen-
etrance, the HFE gene (implicated in hereditary hemochroma-
tosis) scored 11 because of the availability of highly effective 
and noninvasive preventive measures. By contrast, some genes 
that were considered actionable by the ACMG, such as SDHB, 
SDHC, and SDHD (associated with hereditary pheochromo-
cytoma/paraganglioma susceptibility) received scores below 
11 because of limited evidence that biochemical screening in 
an otherwise asymptomatic individual would produce better 
 long-term outcomes than treatment upon onset of symptoms. 
Other genes, such as MYH11 and MYLK (which have recently 
been implicated in familial thoracic aortic aneurysm and dis-
section), could be considered to have effective interventions by 
analogy to other well-known conditions, but they scored lower 
because of a limited knowledge base, which precludes accurate 
assessment of penetrance.
As demonstrated by the range of scores observed for the 
selected gene–disease pairs, actionability is a continuum rather 
than a binary state. Using the random genes as a benchmark, 
21/111 (19%) scored ≥11, while 30/111 (27%) scored ≥10. The 
LVBC chose to consider genes with a score ≥11, essentially the 
top quintile, as meeting the threshold of actionability for inclu-
sion in the revised bin 1 list. This yields a list of 168 genes repre-
senting 176 gene–disease pairs from the total 372 pairs scored. 
The fact that 19% of random genes associated with single-gene 
disorders scored ≥11 suggests that as many as 500 genes of the 
≥3,000 single-gene disorders might rise to this threshold of 
actionability. Thus, we have not yet identified all of the “action-
able” gene–disease pairs, and a systematic screen of single-gene 
disorders is needed. Furthermore, scores are subject to change 
depending on advances in medical genetics, which will likely 
increase some scores over time.
DIsCUssION
Management of the vast range of heterogeneous information 
generated when genomic analysis is undertaken remains one of 
the most challenging aspects of applying genomics in the clini-
cal realm. Patient preferences must be taken into account, espe-
cially with regard to genomic findings that have limited clinical 
actionability. Individuals may make greatly varying choices 
regarding whether they want to learn about different types 
of genomic findings; we are studying these preferences and 
the parameters that influence them as part of the NCGENES 
study. However, just as there are incidentally discovered labora-
tory values that are flagged as “critical” levels, or radiographic 
findings that require clinical action, it follows that when cer-
tain genomic findings exceed a threshold of actionability, the 
default procedure should be to provide those results as part of 
the routine protocol when performing clinical genome-scale 
sequencing tests.
It is thus critical to define a subset of clinically actionable 
genomic findings that are likely to be accepted by most indi-
viduals and allow a standardized and streamlined process for 
informed decision making in clinical genome-scale diagnostic 
testing. Otherwise, the decision about returning genomic find-
ings could (at the reductio ad absurdum extremes) be relegated 
to an all-or-none choice irrespective of the actionability of the 
information, or a nearly infinite menu of potential findings 
organized at the level of certain genes or even specific variants. 
Neither of these options seems tenable in the current clinical 
setting.
It should be stressed that a policy of routine return of a small 
subset of genomic findings does not preclude patient choice 
by means of an informed “opt-out” at the initiation of test-
ing, as now endorsed by the ACMG. In addition, this policy 
does not prohibit laboratories from offering additional catego-
ries of non–medically actionable genomic information (what 
we refer to as “bin 2”) as an “opt-in” to those who desire such 
information, with appropriate education and decision making. 
Nevertheless, any such menu of options needs to be articulated 
before consent and analysis, which calls for an a priori process 
to define which gene–disease pairs fall into any given category.
This article describes the delineation of a novel semiquantita-
tive metric providing a transparent definition of clinical action-
ability and a framework for evaluating criteria in a streamlined 
fashion. We outline criteria for actionability generally similar to 
other expert deliberative processes.5,15 However, this framework 
is unique in that the dimensions of actionability can be assessed 
consistently across different types of disorders. The results 
indicate that, as expected, the ACMG list is enriched for genes 
that achieve high scores for actionability, both supporting their 
inclusion in a recommended list and generally reinforcing the 
parameters used in the current assessment. Future versions of 
the ACMG list could be informed by this scoring metric, or one 
similar to it, in order to remove genes that fall below a stringent 
threshold and to include additional genes with scores equiva-
lent to those on the current recommended list. The percentage 
of individuals who will have such findings is predictable and 
depends on the list of gene–disease pairs being evaluated and 
the stringency with which variants are selected for return.3,15–17
Nuances in application of the semiquantitative metric
The subcategories of the metric reflect the clinical impact of a 
condition (severity and likelihood of a given outcome) while 
balancing the potential benefits (effectiveness of interventions) 
and harms (burden of intervention), thus approximating the 
clinical utility of revealing incidental/secondary findings in a 
presymptomatic individual. Each of these facets is necessary 
to include, despite the subjectivity inherent in scoring some of 
them. For example, both periodic phlebotomy (as in the case of 
hemochromatosis) and surgical removal of the stomach to pre-
vent diffuse gastric cancer (in the case of CDH1 mutations) are 
highly effective measures to prevent morbidity and mortality, 
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yet the burdens of these interventions are dramatically different 
and therefore greatly affect the concept of actionability when 
considering the return of genetic information in a setting in 
which the individual is not likely to have overt symptoms.
Scoring each category on a 0–3 scale allows for a limited 
degree of granularity that captures the qualitative nature of 
certain categories (e.g., effectiveness and burdens of inter-
vention). It would be difficult, and potentially problematic, 
to spread the range of scores into finer subdivisions or to 
develop a more complex nonlinear scoring system. That said, 
different scoring systems could be explored should there be 
a compelling rationale to do so. In addition, customized 
gene lists could be generated for other contexts by apply-
ing weighting schemes or selecting a different threshold. 
For example, one might envision that selection of genes for 
primary screening of the general population should demand 
extremely high knowledge and efficacy scores, and those 
components of the metric could be weighted accordingly. 
In general, differential weighting of criteria will change the 
rank order of scores that are close to one another, and will 
primarily affect gene–disease pairs near the threshold used 
to define actionability. However, those with scores farther 
away from the chosen threshold would be much less likely to 
have their position above or below the threshold affected by 
changes in weighting. Finally, the evidence used in establish-
ing the scores can be explicitly defined, and the scores can be 
updated to incorporate new evidence. Thus, the semiquan-
titative metric provides a structured framework and a more 
nuanced and transparent method for defining a list of clini-
cally actionable genes than would be possible with expert 
consensus approaches.
In practice, the LVBC established a set of conventions for 
scoring different categories (see Table  1 for examples). It is 
challenging to directly compare the severity of conditions that 
lead to bodily harm, such as death or organ failure, with condi-
tions that lead to physical or cognitive impairment. The sever-
ity score is thus intended to judge the relative severity between 
disparate conditions. The likelihood of a given outcome is 
the most quantitatively definable component of the metric, 
although data are lacking for many conditions, requiring either 
an estimate with some uncertainty (reflected in a lower score 
for knowledge base) or a score of 0 when the available data 
are simply too limited to make a reasonable assessment, as in 
the case of autosomal-dominant conditions with only a few 
patients reported in the medical literature.
In the absence of definitive end points, the effectiveness of 
interventions for different clinical outcomes often relies on 
expert opinion. The LVBC generally considered the screening 
or preventive measures that all individuals with a positive find-
ing would be expected to undergo, rather than more definitive 
treatments that would be required only in those who manifest 
symptoms. By any measure, the burden of intervention is the 
most subjective and personally nuanced aspect of the metric. It 
is likely that different individuals hold different views on what is 
acceptable and what constitutes an unreasonable burden in the 
context of their own life experiences. Thus, while we fully rec-
ognize that it can be difficult to assess the burden of a particular 
intervention for an individual, we attempted to define a scoring 
rubric that could roughly define the relative burdens of inter-
ventions across the population. This score could be replaced in 
the future by a more quantitative measure derived from dis-
crete choice experiments or other means of assessing relative 
values, such as the methods used to measure quality-adjusted 
life-years.
Finally, the knowledge base score was applied as a single 
measure reflecting the degree to which each component of the 
score could be confidently defined. Alternatively, a knowledge 
score could be assigned to each component separately based 
on the knowledge base for that element. While more compli-
cated, such an approach would provide greater granularity. The 
strength of the gene–disease association itself is embedded in 
the knowledge base score, since less well-described conditions 
rarely have sufficient knowledge to accurately score certain ele-
ments of the metric. However, we do not intend for this metric 
to be used as a stand-alone measure of the clinical validity of a 
gene–disease association.
Disorders that predispose to thoracic aortic aneurysm and 
dissection illustrate certain nuances of scoring. These condi-
tions convey an increased risk of sudden death due to dissec-
tion, and the typical intervention is to implement a vascular 
imaging screening program. This intervention is a highly effec-
tive and noninvasive means to detect and monitor the size of 
an aneurysm before it poses significant danger of acute dis-
section. More invasive intervention (i.e., vascular surgery) is 
required only if the individual develops a clinically significant 
aneurysm. Overall, this combination of interventions would 
be a highly effective and generally acceptable way to manage 
the risk of sudden death due to an aortic dissection, although 
in some conditions the risk of dissection is not directly related 
to aneurysm size, in which case screening would be less effec-
tive. In addition, the effectiveness of an intervention for more 
rare conditions, such as MYLK-associated thoracic aortic aneu-
rysm and dissection, must be extrapolated based on analogy 
to related conditions because of the lack of information avail-
able regarding the effectiveness of interventions specific to that 
condition.
Potential limitations
The current metric does not account for certain contextual 
factors, such as the age of the individual, the typical age at 
onset of disease or the age at which clinical actions would be 
implemented in a presymptomatic individual, the sex of the 
individual, the general availability and cost of recommended 
preventive strategies, or the ability of relevant genetic lesions 
to be detected. Given these limitations and the necessarily sub-
jective nature of any assessment of actionability, the scores and 
evidence base generated by the application of the semiquantita-
tive metric are best considered an initial starting point for more 
nuanced discussions about individual conditions or particular 
clinical applications.
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Certain features of the metric could lead to minor irregu-
larities in scoring. For example, if the LVBC decided that a 
proposed intervention for a given condition was considered 
ineffective (score = 0), then no score could be assigned to reflect 
the “burden” of that intervention because the additional points 
would inflate the final score. However, If the proposed interven-
tion was considered even “minimally” effective, the total score 
could swing by as much as four points (effectiveness = 1 and 
burden = 3 points for a minimally invasive intervention). This 
impact could be partially mitigated by weighting schemes that 
emphasize the contribution of the effectiveness of the interven-
tion over the burden score to the overall total.
The final scores for each gene–disease pair were determined 
through consensus of the LVBC. This process was not amenable 
to evaluation of interrater variability in scoring, but in practice 
we found that the semiquantitative metric facilitated more effi-
cient discussions and greater consistency than earlier attempts 
to arrive at consensus without a structured framework. It could 
be argued that this process simply replaces a single idiosyn-
cratic expert consensus about “actionability” (the current state 
of other deliberative processes) with several different poten-
tially idiosyncratic decisions. However, assessment of scores 
for each criterion permits more systematic evidence curation 
and updating, as well as a more flexible approach to weight-
ing the importance of different criteria, than would be possible 
otherwise.
Finally, in some cases review of the scores by domain experts 
may prompt revisions based on deeper understanding of the 
clinical scenario or greater awareness of literature that was not 
captured in our review process. In other cases medical advances 
may increase the overall scores by improving the knowledge 
base and perhaps the efficacy of interventions for many condi-
tions. It is expected that there will be a need for ongoing assess-
ment of clinical actionability and updating of results, which 
again is streamlined by the existence of a structured framework.
Conclusions and future questions
We have presented a framework that defines five aspects of clin-
ical actionability, evaluates them qualitatively, and effectively 
distinguishes between lists of genes deemed to be potentially 
actionable by expert opinion versus randomly selected genes. 
This framework is flexible and can be adapted to different con-
texts. It is too early to know whether it is more efficient or more 
reliable than other expert consensus approaches, or whether 
it ultimately leads to better clinical outcomes. In addition, it 
remains to be determined whether other groups would arrive 
at the same scores. However, the inherent transparency of the 
framework facilitates comparison between different efforts, 
critical evaluation, and updating of the scores as new knowl-
edge accrues as a result of the constantly evolving medical lit-
erature. We anticipate using this or a similar metric to evaluate 
all human disease genes to guide the application of genomic 
medicine.
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